CytomX Therapeutics(CTMX)
SOUTH SAN FRANCISCO, CA
BiotechnologyFocus: Protease-Activated Antibodies, 'Probodies'
CytomX Therapeutics is a life sciences company focused on Protease-Activated Antibodies, 'Probodies'.
Oncology
Funding Stage
PUBLIC
Open Jobs
0
Pipeline & Clinical Trials
CX-801
Solid Tumor, AdultCX-904
Solid TumorsClinical Trials (1)
NCT05387265A Trial to Find Safe and Active Doses for an Investigational Drug, CX-904, for Patients With Advanced Solid Tumors
Phase 1CX-2051
Solid Tumor, AdultClinical Trials (1)
NCT06265688First In Human Study of CX-2051 in Advanced Solid Tumors
Phase 1CX-188
Solid Tumor, AdultClinical Trials (1)
NCT03706274PROCLAIM-CX-188: A Trial to Find Safe and Active Doses of an Investigational Drug CX-188 for Patients With Solid Tumors
Phase 1CX-072
Solid TumorClinical Trials (1)
NCT03013491PROCLAIM-CX-072: A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas
Phase 1/2CX-2029
Solid Tumor, AdultClinical Trials (1)
NCT03543813PROCLAIM-CX-2029: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2029 for Patients With Solid Tumors or DLBCL
Phase 1/2CX-2009
Solid Tumor, AdultClinical Trials (1)
NCT03149549PROCLAIM-CX-2009: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2009 for Patients With Selected Solid Tumors
Phase 1/2CX-2009
NeoplasmsClinical Trials (1)
NCT04596150Study to Evaluate the Safety and Antitumor Activity of CX-2009 Monotherapy and in Combination With CX-072 in Advanced Breast Cancer
Phase 2CX-072
Solid TumorClinical Trials (1)
NCT03993379PROCLAIM: CX-072-002: Study of PD-L1 Probody Therapeutic CX-072 in Combination With Other Anticancer Therapy in Adults With Solid Tumors
Phase 2Open Jobs (0)
No open positions listed yet. Check their careers page directly.
Interview Prep Quick Facts
Founded: 2000
Portfolio: 8 clinical trials
SEC Filings: 2 available
Financials (FY2024)
Revenue
$101M90%
R&D Spend
$78M(77%)30%
Net Income
-$569KCash
$17M